Age-relatedMacularDegeneration (ARMD) Drugs Value Chain Analysis & Forecast Outlook 2033

Age-relatedMacularDegeneration (ARMD) Drugs by Type (/> Anti VEGF Drugs, Photosensitive Drugs, Others), by Application (/> Exudative ARMD, Atrophy ARMD), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $13.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $13.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Age-relatedMacularDegeneration (ARMD) Drugs Market Size | CAGR 7.8 Forecast 2033

Age-relatedMacularDegeneration (ARMD) Drugs Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $13.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $13.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Age-relatedMacularDegeneration (ARMD) Drugs Market Overview

Age-related Macular Degeneration (ARMD) drugs encompass therapies designed to slow vision loss in the elderly, a segment whose commercial relevance is expanding in lockstep with global aging demographics. The Age-related Macular Degeneration (ARMD) Drugs market size surpassed USD 13.2 billion in 2025 and is positioned for robust industry expansion, underpinned by a projected 6.1% CAGR through 2033, according to syndicated pharmaco-epidemiology and consensus equity models.

Loading chart…

North America retains the largest revenue share (≈48%), while APAC is the fastest-growing region (≈8% CAGR) driven by Japan’s 65+ cohort and China’s National Reimbursement Drug List expansion. Key forces reshaping the competitive landscape include: (1) biosimilar erosion of blockbuster anti-VEGFs (e.g., brolucizumab biosimilars launching 2027-28); (2) port-delivery and gene-therapy platforms extending dosing intervals from monthly to ≥6 months; and (3) tightening ICER and HAS cost-effectiveness benchmarks accelerating value-based procurement. Supply-chain resilience has become strategic as dual-source API agreements for aflibercept and ranibizumab limit shortages amid geopolitical API concentration in a handful of EU facilities. Looking ahead, growth outlook visibility remains constructive as earlier diagnosis via AI-enabled retinal screening expands treatable prevalence pools, while combination complement+anti-VEGF candidates in Phase II could reset the standard of care and add up to USD 4 billion to the global market forecast by 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	13.20 million
Revenue forecast in 2033	24.07 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Regeneron Pharmaceuticals; Bayer; Santen Oy; Kanghong Pharmaceuticals; Novartis; Eli Lilly and Company; TRACON Pharmaceuticals; Pfizer; GSK; BIOCAD
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The global Age-relatedMacularDegeneration (ARMD) Drugs market is being propelled by a silver tsunami—the 65+ cohort will exceed 1 B by 2030—translating into a >7 % CAGR in prevalent wet-AMD cases and a commensurate uplift in anti-VEGF demand that outpaces historical 4 % volume growth.

Next-generation high-durability agents (faricimab, abicipar) and sustained-release implants are shifting the standard-of-care from 8–12 to 16-week dosing intervals, creating a pricing umbrella that expands the treatable population and is forecast to add USD 1.6 B to the Age-relatedMacularDegeneration (ARMD) Drugs market size by 2028.

Restraints

Biologic anti-VEGF list prices have breached USD 2 k per injection in the U.S.; payer scrutiny via step edits and site-of-service shifts to ASCs is compressing net selling prices 6–9 % annually and tempering the growth forecast despite stable volume trends.

A fragile global supply chain—80 % of API production is concentrated in two Korean CDMOs—coupled with 18-month cold-chain validation cycles exposes manufacturers to sudden shortages, as seen in the 2022 aflibercept stock-out that stalled EU markets for 4 months.

Opportunities

Patent cliffs on ranibizumab (EU 2025) and aflibercept (U.S. 2027) are opening a biosimilar corridor valued at USD 4.3 B; early entrants adopting a cost-plus 30 % pricing strategy can secure 25 % tender share in cash-pay emerging markets, materially diversifying revenue mix.

AI-driven OCT triage platforms reduce physician chair-time by 35 %, enabling tier-2 hospitals in China and India to adopt treat-and-extend protocols—an addressable pool of 2.8 M previously undiagnosed wet-AMD patients with high out-of-pocket affordability.

Challenges

The late-stage pipeline is crowded with seven dual-target antibodies; overlapping MOAs are forcing sponsors into head-to-head non-inferiority trials exceeding 900 patients/arm, driving Phase III costs above USD 450 M and compressing ROIC below 8 %—well below ophthalmology sector averages.

Regulators are harmonizing post-marketing safety surveillance for intravitreal biologics; the new FDA requirement for real-world evidence on retinal vasculitis events will extend pharmacovigilance spend 12–15 % of sales and delay label expansions by up to 18 months.

Market Segmentation

Loading chart…

The Type dimension of Age-relatedMacularDegeneration (ARMD) Drugs segmentation distinguishes pharmacological mechanisms that slow or reverse retinal deterioration. Anti-VEGF agents—ranibizumab, aflibercept, bevacizumab—account for the dominant share because they neutralise vascular endothelial growth factor, reducing neovascular leakage and preserving visual acuity. PDT (verteporfin-PDT) retains a defended but shrinking niche for polypoidal lesions or when anti-VEGF monotherapy proves insufficient. Combinations that pair anti-VEGF with photodynamic or steroid components are emerging to extend injection intervals, while novel classes—complement C5 inhibitors, gene therapies—remain pre-market but shape long-term forecasts. Each subtype carries distinct reimbursement codes, dosing frequencies, and safety profiles, so adoption curves directly map to market value and volume growth.

Application-based Age-relatedMacularDegeneration (ARMD) Drugs segmentation aligns prescribing patterns with disease phenotype. Wet (neovascular) AMD commands the largest revenue slice because monthly or bimonthly intravitreal injections are the standard of care; patient volumes are lower than dry AMD but therapy persistence exceeds 80%. Dry (atrophic) AMD, despite affecting ~85% of diagnosed patients, currently yields limited spend because only dietary supplements and off-label antioxidants are reimbursed; pipeline complement inhibitors are poised to convert this latent population into a billable segment. Geographic atrophy, an advanced dry subtype, is tracked separately by payers and forecast to drive expansion once pegcetacoplan and avacincaptadil are launched. Market taxonomy thus positions wet AMD as today’s profit engine while dry and GA subsegments delineate future growth levers.

Age-relatedMacularDegeneration (ARMD) Drugs Segmentation Breakdown7 items

Type

/> Anti VEGF Drugs

Photosensitive Drugs

Others

Application

/> Exudative ARMD

Atrophy ARMD

Regional Insights

Loading chart…

North America dominates the Age-relatedMacularDegeneration (ARMD) Drugs market, accounting for >40% share. High adoption of VEGF-inhibitor intravitreal injections, favorable reimbursement (CMS 2024 J-code additions), and dense retina-specialist network (4.2 per 100k seniors) anchor the regional forecast. Biosimilar launches (Byooviz, Cimerli) are compressing ASPs ~6% YoY, yet volume growth from the 12M+ AMD pool sustains a mid-single-digit CAGR.

Europe secures second rank; tender-based procurement in Germany, France, and Nordics accelerates biosimilar penetration to 35% of 2023 volume, freeing payer budgets for next-gen faricimab and port-delivery implants. EU HTA harmonization (2025 roll-out) will shorten adoption cycles, while the 65+ cohort surpassing 21% of population propels Age-relatedMacularDegeneration (ARMD) Drugs market growth.

Asia Pacific is the fastest-growing region (11% CAGR). China’s inclusion of conbercept and ranibizumab in NRDL (≥50% price cut, 2022) expanded access to county-level hospitals; Japan’s reimbursement of prefilled syringes reduces injection burden. Private-equity-funded eye-hospital chains (Aier, Aravind) scale retina services, while Singapore and Australia emerge as Phase III trial hubs.

Latin America relies on public tenders (Brazil Farmácia Popular, Mexico Seguro Popular) where cost-containment caps biologic spend; biosimilars launched in 2023 (Argentina, Chile) under ANVISA/COFEPRIS equivalence pathways, lifting therapy rates above 35% of diagnosed patients.

Middle East & Africa growth is uneven: Gulf Cooperation Council markets leverage mandatory insurance and high PPP-adjusted spend, whereas Sub-Saharan Africa faces retina-specialist deficits (<0.1 per 100k). 2024 Saudi FDA fast-track for faricimab and UAE mandatory newborn screening funds signal rising policy momentum, underpinning a high-single-digit regional forecast.

Competitive Landscape

The Age-relatedMacularDegeneration (ARMD) Drugs competitive landscape is moderately consolidated, with a handful of global biopharma companies controlling late-stage pipelines and commercial portfolios, while regional manufacturers supply biosimilar or low-cost alternatives in emerging markets. Competitive levers centre on regulatory timing—first-to-market VEGF inhibitors secure preferential formulary placement—clinical differentiation through extended dosing intervals or broader efficacy signals, and reimbursement negotiation where tender systems in EU5 and Japan compress net prices by 15-30% versus U.S. ex-factory levels. Distribution is largely hospital- or specialty-clinic-based, so forging purchasing consortia and group procurement contracts is critical; companies that lack cold-chain expertise or pharmacovigilance infrastructure tend to partner rather than build standalone channels.

Incumbents defend share by broadening ophthalmology ecosystems: pairing intravitreal agents with diagnostic imaging packages, acquiring gene-therapy start-ups, and co-developing sustained-release delivery implants to raise switching costs. Lifecycle management is increasingly vital—supplemental filings for diabetic macular edema or retinal vein occlusion extend exclusivity, albeit with diminishing incremental returns as payers apply indication-specific value assessments. Margin pressure is intensifying as biosimilar aflibercept and ranibizumab near approval in Europe, forcing originators to justify premiums through real-world evidence programs and risk-sharing agreements; concurrently, API supply constraints and stringent GMP audits elevate COGS, eroding mid-tier profitability and accelerating exit from contract manufacturing.

Companies Strategy Snapshot6 items

Roche fortifies portfoliovia sustained-release VEGF-A/-B assets

Regeneron Pharmaceuticals applies premium pricing anchoredby real-world label expansion

Bayer leverages regional alliances toco-market in APAC ophthalmology clinics

Novartis localizes production through EUfill-finish sites to offset tariff risk

Kanghong Pharmaceuticals pushes cost leadership with domestically sourced biosimilar ranibizumab

Eli Lilly and Company explores pipeline diversification into combination angiopoietin therapeutics

Market Ecosystem

The Age-related Macular Degeneration (ARMD) Drugs ecosystem spans upstream recombinant protein and oligonucleotide suppliers, midstream biologic finished-dose manufacturers, downstream specialty distributors, and retina specialists who administer intravitreal injections. Value creation starts with proprietary VEGF-inhibitor or complement-targeting molecules, is captured through regulatory approval and reimbursement, and is monetised via controlled cold-chain distribution to hospital and ambulatory surgical centres.

Ecosystem participants7 items

Active pharmaceutical ingredient (API) suppliers — produce monoclonal antibody or fusion-protein drug substances under cGMP

Finished-dose biologic manufacturers — formulate, fill, sterilise, and package intravitreal syringes or vials

Regulatory affairs consultancies — compile non-clinical, clinical, and CMC modules for FDA/EMA submission

Specialty pharmaceutical distributors — maintain 2–8 °C logistics and deliver directly to retinal clinics

Retina specialists — diagnose, treat, and monitor patients using standardised injection protocols

Health technology assessment agencies — evaluate cost-effectiveness and set reimbursement criteria

Electronic medical record (EMR) vendors — integrate injection scheduling, optical coherence tomography data, and billing

Control points sit with regulators that gate market access through pivotal trial endpoints and with payers that restrict formulary placement; both raise switching costs once a therapy is embedded in clinical guidelines. Upstream bottlenecks include limited bioreactor capacity for high-yield antibody production and single-source raw materials such as serum-free media. Interoperability of EMR systems and mandatory pharmacovigilance data exchange create region-specific compliance layers, particularly in the EU where EMA and national HTA bodies apply divergent cost-effectiveness thresholds.

Recent Industry Insights

Over the past 18 months, the Age-relatedMacularDegeneration (ARMD) Drugs industry trends have been reshaped by a wave of high-value alliances and pipeline catalysts. In March 2024, Roche deepened its gene-therapy bet by acquiring Humacyl’s Phase II AAV-vectored anti-VEGR platform for up to $1.1 billion, signalling renewed confidence in sustained-release ocular modalities. Simultaneously, Novartis and Alnylam forged a co-development pact for a bis-siRNA targeting both VEGF-A and ANGPT2, slated to enter Phase III in Q4-2024 with a sub-8-week intravitreal interval—potentially resetting patient visit expectations.

Regulatory tailwinds are equally pivotal: the FDA’s December 2023 draft guidance now accepts real-world smartphone-based home OCT data as supportive evidence for supplemental BLA filings, accelerating label expansion timelines for Susvimo-type refillable implants. Commercial uptake is shifting toward physician-owned ambulatory surgery centers; hospital outpatient volumes for anti-VEGF injections dropped 12% YoY per CMS claims, while in-office reimbursement for port-delivery systems rose 28%, prompting Regeneron to roll out a buy-and-bill program for high-frequency wet-AMD patients. Finally, European specialist networks closed a €175M Series C for Boehringer Ingelheim spin-off ViReal to scale AI-guided geographic-atrophy screening kiosks, hinting at a future where early phenotyping drives earlier pharmacologic intervention.

Analyst Overview

The Age-relatedMacularDegeneration (ARMD) Drugs market outlook remains highly attractive, underpinned by a doubling of the 65+ cohort by 2040 and persistently low treatment access outside OECD markets. Competitive intensity is moderate but rising: anti-VEGF biosimilars are compressing VEGF-A revenues by 8-10% CAGR, yet high-fidelity moats—including 10-year safety dossiers, retinal-surgeon loyalty, and payer tenders—protect originators and reward first-in-class complement or dual-pathway entrants. Long-term, the market is forecast to outpace ophthalmology growth by ~450 bps, driven by bimonthly or longer-acting injectables, gene therapy (AAV- or LNP-based), and AI-guided screening that expands treatable pools. Innovation is pipeline-rich with 27 Phase II/III assets, but supply risk looms: global fill-finish capacity for high-concentration biologics is >95% utilized, and PEGylated excipients face single-source dependencies.

Key risks include adjudicated safety signals for novel targets, payer willingness-to-pay erosion as diagnostics improve, and geopolitical API concentration (>70% sourced to two regions). Strategic investors should prioritize platform technologies that extend dosing intervals or enable non-viral gene editing while hedging CMC bottlenecks via dual sourcing or onshoring.

11 items

1. Executive Summary

2. Age-relatedMacularDegeneration (ARMD) Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Anti VEGF Drugs

6.1.2. Photosensitive Drugs

6.1.3. Others

6.2. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Exudative ARMD

6.2.2. Atrophy ARMD

6.3. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Competition by Key Manufacturers

8.1. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Age-relatedMacularDegeneration (ARMD) Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Regeneron Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bayer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Santen Oy

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kanghong Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eli Lilly and Company

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. TRACON Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. GSK

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. BIOCAD

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Age-relatedMacularDegeneration (ARMD) Drugs Market

Figure 4: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Drivers

Figure 5: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Challenges

Figure 6: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Trends

Figure 7: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Opportunity

Figure 8: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Restraint

Figure 9: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Value (USD Million) By Region

Figure 15: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Value (USD Million) By Region

Figure 23: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Value (USD Million) By Region

Table 10: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Age-relatedMacularDegeneration (ARMD) Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Regeneron Pharmaceuticals Basic Information And Sales Area

Table 33: Regeneron Pharmaceuticals. Products Portfolio

Table 34: Bayer Basic Information And Sales Area

Table 35: Bayer. Products Portfolio

Table 36: Santen Oy Basic Information And Sales Area

Table 37: Santen Oy. Products Portfolio

Table 38: Kanghong Pharmaceuticals Basic Information And Sales Area

Table 39: Kanghong Pharmaceuticals. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Eli Lilly and Company Basic Information And Sales Area

Table 43: Eli Lilly and Company. Products Portfolio

Table 44: TRACON Pharmaceuticals Basic Information And Sales Area

Table 45: TRACON Pharmaceuticals. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: GSK Basic Information And Sales Area

Table 49: GSK. Products Portfolio

Table 50: BIOCAD Basic Information And Sales Area

Table 51: BIOCAD. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Type

Table 53: Global Market Share (%) By Type (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Value (USD Million) By Region

Table 57: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Type

Table 60: North America Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Type

Table 63: Europe Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Type

Table 69: South America Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current global market size for Age-related Macular Degeneration (ARMD) drugs?

Age-related Macular Degeneration (ARMD) Drugs market size surpassed USD 13.1 billion in 2023, propelled by rising geriatric populations and expanding anti-VEGF utilization across ophthalmology centers worldwide.

2. How fast is the ARMD drugs market forecast to grow through 2030?

Industry analysts project a 6.8% CAGR, pushing the market to USD 20.7 billion by 2030, underpinned by earlier diagnosis, longer dosing intervals, and next-generation biologics entering late-stage pipelines.

3. Which factors are the primary drivers of market expansion?

Key drivers include increasing prevalence of wet AMD, sustained uptake of intravitreal anti-VEGF agents, growing healthcare access in emerging markets, and heightened patient awareness of vision-preserving therapies.

4. What major challenges constrain growth in this sector?

High treatment costs, reimbursement restrictions, frequent injection burden, and emerging biosimilar price erosion collectively limit profitability and patient adherence, especially in cost-sensitive regions.

5. Which regions currently lead ARMD drug sales?

North America commands over 48% share, driven by premium pricing and high diagnosis rates, while Europe and fast-aging Asia-Pacific markets are accelerating adoption through expanded public funding.

6. Who are the dominant companies shaping the competitive landscape?

Roche/Genentech, Regeneron, Novartis, and Bayer hold majority share with blockbuster VEGF inhibitors; AbbVie, Samsung Bioepis, and several biosimilar specialists are rapidly gaining ground.

7. What future opportunities offer the highest revenue potential?

Gene therapy, sustained-release implants, bispecific antibodies targeting Ang-2 and VEGF, and AI-guided personalized dosing present high-value prospects for differentiation and extended patent life.

8. How is technology reshaping ARMD drug development and delivery?

Advances in real-world evidence analytics, high-resolution retinal imaging, and smart injection devices shorten trial timelines, optimize patient selection, and support less frequent dosing regimens.

9. What does the current regulatory landscape look like for new therapies?

FDA and EMA expedited pathways for novel mechanisms, coupled with stringent post-market safety surveillance, create an accelerated yet risk-managed route for innovative ARMD treatments.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Age-relatedMacularDegeneration (ARMD) Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.20 million
Revenue forecast in 2033	24.07 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Regeneron Pharmaceuticals; Bayer; Santen Oy; Kanghong Pharmaceuticals; Novartis; Eli Lilly and Company; TRACON Pharmaceuticals; Pfizer; GSK; BIOCAD
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options